Learn how genomics-based biomarker approaches can empower the success of your immuno-oncology clinical development programs by implementing a tailored biomarker strategy.
How blinding benefits both the patient and the investigator and drug encapsulation is an effective blinding method.
Real world experiences, pitfalls and best practices that can improve the efficiency of clinical development when centralizing and managing third party vendors.
The development of immuno-oncology (I/O) medicines offer a new era of treatment options for physicians and patients. However, the level of sophistication required for biomarker selection, trial design, technology implementation, testing, and commercialization planning is unprecedented. Learn more about how clinical trial laboratories are utilizing multiple technologies and solutions to support immuno-oncology clinical development.
Cutting edge genomics technologies to power and enhance immuno-oncology (IO) trials where reporting transcriptional response pairs a person to therapy without multiple biopsies.
MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens.
Gene expression and analysis for detection of 11 Immune Landscape Signatures.
Best practices for rapid test development and regulatory approvals.
Using anatomic pathology for biomarker development in clinical trials can help predict and assess how a patient will respond to immuno-oncology therapies
Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
|
|
|
|
|
|
|
|
|